Outcome of lamotrigine treatment in juvenile myoclonic epilepsy

Acta Neurologica Scandinavica

Volumn 124, Issue 1, 2011, Pages 22-27

  Bodenstein Sachar, H ^a,b   Gandelman Marton, R ^b,c   Ben Zeev, B ^a,b   Chapman, J ^a,b   Blatt, I ^a,b  

^a SHEBA MEDICAL CENTER   (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

^c ASSAF HAROFEH MEDICAL CENTER   (Israel)

Author keywords

Generalized tonic clonic seizures; Juvenile myoclonic epilepsy; Lamotrigine; Myoclonic seizures

Indexed keywords

CARBAMAZEPINE; GABAPENTIN; LAMOTRIGINE; PHENYTOIN; VALPROIC ACID;

ADOLESCENT; ARTICLE; DEMOGRAPHY; DRUG EFFICACY; DRUG TREATMENT FAILURE; ELECTROENCEPHALOGRAPHY; FEMALE; HUMAN; JUVENILE MYOCLONIC EPILEPSY; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; MYOCLONUS EPILEPSY; OBSERVATIONAL STUDY; PREDICTION; REMISSION; RETROSPECTIVE STUDY; THERAPY DELAY; TONIC CLONIC SEIZURE; TREATMENT OUTCOME; TREATMENT RESPONSE;

ADOLESCENT; ANTICONVULSANTS; CHILD; FEMALE; HUMANS; MALE; MYOCLONIC EPILEPSY, JUVENILE; PROGNOSIS; RETROSPECTIVE STUDIES; SEIZURES; TREATMENT OUTCOME; TRIAZINES; YOUNG ADULT;

EID: 79958259862     PISSN: 00016314     EISSN: 16000404     Source Type: Journal    
DOI: 10.1111/j.1600-0404.2010.01472.x     Document Type: Article

References (24)

1. Mohanraj R, Brodie M. Outcomes of newly diagnosed idiopathic generalized epilepsy syndromes in a non-pediatric setting. Acta Neurol Scand 2007;115:204-8.
2. Renganathan R, Delanty N. Juvenile myoclonic epilepsy: under-appreciated and under-diagnosed. Postgrad Med J 2003;79:78-80.
3. Commission on Classification and Terminology of the International League Against Epilepsy. Proposal for revised international classification of epilepsies, epileptic syndromes and related seizure disorders. Epilepsia 1989;4:389-99.
4. Jayalakshmi SS, Srinivasa Rao B, Sailaja S. Focal clinical and electroencephalographic features in patients with juvenile myoclonic epilepsy. Acta Neurol Scand 2010;122:115-23.
5. Calleja S, Salas-Puig J, Ribacoba R, Lahoz CH. Evolution of JME treated from the outset with sodium valproate. Seizure 2001;10:424-7.
6. Marson AG, Al-Kharusi AM, Alwaidh M et al. The SANAD study of effectiveness of valproate, lamotrigine or topiramate for generalized and unclassifiable epilepsy: an unblinded randomized controlled trial. Lancet 2007;369:1016-26.
7. Mehndiratta MM, Aggarwal P. Clinical expression and EEG features of patients with JME from North India. Seizure 2002;11:431-6.
8. Gelisse P, Genton P, Thomas P, Rey M, Samuelian JC, Dravet C. Clinical factors of drug resistance in JME. J Neurol Neurosurg Psychiatry 2001;70:240-3.
9. Prasad A, Kuzniecky R, Knowlton R et al. Evolving antiepileptic drug treatment in JME. Arch Neurol 2003;60:1100-5.
10. Gram L, Schmidt D. Pharmacotherapy in special circumstances. In: Meinardi H, ed. Handbook of clinical neurology, vol. 73 (29): the epilepsies, part two. Amsterdam: Elsevier Science BV, 2000;369-79.
11. Leppik IE. Role of new and established antiepileptic drugs. Epilepsia 1998;39(Suppl. 5):2-6.
12. Morris G, Hammer A, Kustra R, Messenheimer J. Lamotrigine for patients with JME following prior treatment with valproate: results of an open-label study. Epilepsy Behav 2004;5:509-12.
13. Buchanan N. The use of lamotrigine in juvenile myoclonic epilepsy. Seziure 1996;2:149-51.
14. Karceski S, Morrell MJ, Carpenter D. Treatment of epilepsy in adults: expert opinion, 2005. Epilepsy Behav 2005;7(Suppl. 1):1-64.
15. Wheless JW, Clarcke DF, Arzimanoglou A, Carpenter D. Treatment of pediatric epilepsy: European expert opinion, 2007. Epileptic Disord 2007;9:353-412.
16. Morrow J, Russell A, Gutherie E et al. Malformation risks of anti-epileptic drugs in pregnancy: a prospective study from the UK Epilepsy and Pregnancy Register. J Neurol Neurosurg Psychiatry 2005;10:1-11.
17. Sabers A, Dam M, Rogvi-Hansen B et al. Epilepsy and pregnancy: lamotrigine as main drug used. Acta Neurol Scand 2004;109:9-13.
18. Cunnington M, Tennis P. Lamotrigine and the risk of malformations in pregnancy. Neurology 2005;64:955-60.
19. Mazurkiewicz-Beldzinska M, Szmuda M, Matheisel A. Long-term efficacy of valproate versus lamotrigine in treatment of idiopathic generalized epilepsies in children and adolescents. Seizure 2010;19:195-7.
20. Nicolson A, Appleton RE, Chadwick DW, Smith DF. The relationship between treatment with valproate, lamotrigine and topiramate and the prognosis of the idiopathic generalised epilepsies. J Neurol Neurosurg Psychiatry 2004;75:75-9.
21. Fernando-Dongas M, Radtke R, Vanlandingham K, Husain A. Characteristics of valproic acid resistant JME. Seizure 2000;9:385-8.
22. Dasheiff RM, Ritaccio AL. Characterization of intractable JME: new perspectives on primarily generalized seizures-Abstract. Seizure 1993;2:9-11.
23. Wong I, Mawer G, Sander J, Lhatoo S. A pharmacoepidemiologic study of factors of influencing the outcome of treatment with lamotrigine in chronic epilepsy. Epilepsia 2001;42:1354-8.
24. Matsuoka H. The seizure prognosis of JME. Jpn J Psychiatry Neurol 1992;46:293-6.